In agreement with these findings, Jasmer et al. [146] have recently shown that inhibition of P2Y2R using the selective antagonist AR-C118925 in another animal model of SS resolved sialadenitis, while improving compromised salivary flow. Here, P2RY2 is linked to synovial sarcoma.